Table 10.
(A) Quality of life of metastatic gastric cancer, (patient’s received intervention and chemotherapy simultaneously). (B) Median difference before –after of Quality of Life
| Mean (before) |
Std. deviation |
Std. error |
P-value | Mean (after) |
Std. deviation |
Std. error |
P-value | |
|---|---|---|---|---|---|---|---|---|
| (A) Quality of life in patients with metastatic gastric cancer | ||||||||
| Global quality (BCc1 nanomedicine) |
45.89 | 12.869 | 4.290 | 0.200 | 44.22 | 10.721 | 3.574 | 0.200 |
| Global quality (Placebo) |
49.08 | 13.318 | 3.844 | 0.200 | 49.83 | 13.265 | 3.829 | 0.200 |
| Mean* | Std. deviation | Std. error mean | P-value | |
|---|---|---|---|---|
| (B) Median difference (before–after) of quality of life | ||||
| Quality of BCc1 (before–after) | 1.667 | 7.053 | 2.351 | 0.499 |
| Quality of Placebo (before–after) | − 0.750 | 2.958 | 0.854 | 0.399 |
* Higher score show better global quality of life